lung cancer overview-jtl
DESCRIPTION
An Overview of Lung Cancer:EpidemiologyScreeningHistology/PathologyPathogenesisInvasive and Noninvasive StagingManagementTRANSCRIPT
![Page 1: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/1.jpg)
Lung CancerAn Overview
Wake Forest Baptist Medical CenterRadiation Oncology Department
John T. Lucas Jr. MD, MSCR PGY2
![Page 2: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/2.jpg)
- Epidemiology- Prognosis- Etiology- Screening - Pathogenesis- Workup - Pathology- Staging - Pattern of Spread- Management
Outline
![Page 3: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/3.jpg)
• In 2009, there were 219,000 newly diagnosed cases of lung cancers in the ∼ U.S., accounting for >160,000 deaths. >850,000 worldwide
• This > deaths from colorectal, breast, & prostate ca combined
• The overall 5-yr survival rate for NSCLC is 15%
• Most common stage @ dx ~ Metastatic (30%)– Stage 1 ~ 10% 5 yr OS 50-80%– Stage 2 ~ 20% 5 yr OS 30-70%– Stage 3 ~ 30% 5 yr OS 5-30%– Stage 4 ~ 40% MS 3-6 mo
Best supportive care 8-10mo
Epidemiology
Worldwide
![Page 4: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/4.jpg)
• Blacks have the highest incidence of lung cancer.
• Lung Cancers in smokers– M>F
– Minimal variation in regional incidence
• Lung Cancers in never smokers have different
high risk groups– F>M
– Wide variation in regional incidence
Epidemiology
![Page 5: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/5.jpg)
Is there a role for screening?
-Early Trials – NCI, Mayo-Trial design complicated by lead time, length time bias-Patient selection problems
![Page 6: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/6.jpg)
Lead time bias
• No screening
Signs or symptomsDEATH
SURVIVAL
Screening
Positive test
DEATH
SURVIVAL
![Page 7: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/7.jpg)
• 53,454 persons randomized to either low-dose spiral CT or conventional PA chest radiograph
• Prevalence screen, and two annual incidence screens
• Follow-up through 2009
• High Risk defined as: – age 55 – 74– current or former smoker (quit within the
last 15 years)– at least 30 pack years smoking history
Is there a role for screening?- NLSTDesign
![Page 8: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/8.jpg)
Radiographic Classification
• Benign: benign calcification pattern, fat attenuation, linear morphology, stable for > 2 years
• Abnormal: new nodules > 10 mm diameter, or enlarging nodules > 7 mm not meeting benign criteria or unrelated to neoplastic process
• Indeterminate: new solitary or multiple nodules 4 -10 mm in diameter, or enlarging nodules < 7 mm
• Nodules < 4 mm
Is there a role for screening? - NLST
![Page 9: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/9.jpg)
• If new abnormal nodule was observed
w/u bx etc.
• If new benign appearing lesion
continue screening
• If new benign appearing lesion that is enlarging
w/u bx etc.
Is there a role for screening?- NLSTDesign
![Page 10: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/10.jpg)
Is there a role for screening?- NLSTResults
![Page 11: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/11.jpg)
Is there a role for screening?- NLSTResults
![Page 12: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/12.jpg)
Is there a role for screening?- NLSTResults
- 20% reduction in lung cancer–specific deaths in the LDCT group,
- 247 deaths due to lung cancer per 100 000 person-years in the LDCT group
- 309 deaths per 100 000 person-years in the chest radiography group
![Page 13: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/13.jpg)
Is there a role for screening?- NLSTDiscussion – Risks?
So it works but is it worth it- i.e. is this PSA all over again?
-Overdiagnosis and intervention is a very real risk-60% of cases dx’d by PSA are not likely to result in a (-) in OS
-LDCT is unlikely to occur w/out regulation
-27% of LDCT arm had abnormal finding 96.4% were false positives
-60 days into NLST, 21 patients died 2/2 invasive eval for a abnl finding- 6 of these didn’t have lung ca
-Variation in how nodules are managed could yield excessive risk-CT guided FNA has 15% pneumothorax rate, 6% require chest tube
-Surgery for Lung Ca in trial done at academic centers, known to have >2 fold increase in @ 5yr compared to community centers
![Page 14: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/14.jpg)
Is there a role for screening?- NLSTDiscussion – If applied?
- Informal dividing line b/n cost-effective & not cost-effective is around $50,000/ QALY
- 39.1% of patients screened would have a + finding, -e.g., a nodule 4 mm or larger, and each patient who was positive at baseline screening would undergo two follow-up chest CTs based on current practice standards.
- A 20% mortality reduction would work out to about a 0.04 increase in life-years when divided across the NLST cohort
-Previous estimates of COST/QALY were on the order of $150,000
- Preliminary estimates show additional cost of screening would work out to about $38,000 per QALY
- Alternative?
![Page 15: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/15.jpg)
• Heavy smokers have a 20x excess of lung cancer (ACS cohort study).
• Risk of developing lung cancer in former smokers is around 1/2 (9x vs. 20x) that of current smokers (ACS cohort study).
• There is an RR of 1.2–1.3 for developing lung cancer from passive smoke exposure.
• Nicotine-derived nitrosoaminoketone (NNK)
• <20% of smokers actually develop lung cancer (in the Carotene and Retinol Efficacy Trial, 10-yr cancer risk was 1%–15%).
• Adenocarcinoma is the histologic subtype that is least associated with smoking.
Etiology
![Page 16: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/16.jpg)
Pathogenesis-Smokers vs NonSmokers
![Page 17: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/17.jpg)
Etiology - Nonsmokers
![Page 18: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/18.jpg)
Lung Cancer Herbst, Heymach, and Lippman, M.D. N Engl J Med 2008; 359:1367-1380
Etiology - Genetics
![Page 19: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/19.jpg)
Source: Grace
Etiology - Genetics
![Page 20: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/20.jpg)
![Page 21: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/21.jpg)
• EGFR mut are more sensitive
than WT in vivo & in vitro
• 500-1000 fold compared to WT– 2/2 +apoptosis, cell cycle arrest
• Erlotinib & Gefitinib resistance
was overcome by IR
Pathogenesis- Why do I care? - EGFR
Cancer Res. 2006 Oct 1;66(19):9601-8. Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. Das AK, Sato M, Story MD, Peyton M, Graves R, Redpath S, Girard L, Gazdar AF, Shay JW, Minna JD, Nirodi CS.
![Page 22: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/22.jpg)
• Ras mut are more resistant
than WT in vivo & in vitro
• 2/2 constitutive Raf/MEK/ERK
• Can be overcome by
farnesyltransferase inhibitors
& KSR1 inhibitors
Pathogenesis- Why do I care? - Ras
Bernhard EJ, Stanbridge EJ, Gupta S, et al. Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines. Cancer Res 2000;60:6597–600
Cancer Ther. 2010 Oct;9(10):2724-36. 2010 Sep 28. Pharmacologic inactivation of kinase suppressor of Ras1 sensitizes epidermal growth factor receptor and oncogenic Ras-dependent tumors to ionizing radiation treatment.Xiao H, Zhang Q, Shen J, Bindokas V, Xing HR.
![Page 23: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/23.jpg)
Pathogenesis(80%) NSCLC- Histologic Subtypes:50% Adenocarcinoma-Progenitor: BASC• Bronchoalveolar• Acinar• Papillary
(35%) SCC-Progenitor: Basal Cell
(15%) Large cell-Progenitor: NE Cell• Giant Cell• Clear Cell
(16%) SCLC-Progenitor: NE Cell
![Page 24: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/24.jpg)
- H & P - ROS: PS, weight loss, baseline dyspnea- Physical Exam: note +/- clubbing, hoarseness, pain, palsy,
sympathetic deficit- (SH: Tobacco, Work/Home exposure)
- CBC, CMP, +/- ABG, +/- Alk Phos, LDH- FDG-PET, CT C/A/P
- Eval tumor, nodes, distant sites, & r/o other pathology (i.e. PNA)
- MRI Brain if:- LN+ Nonsquamous histology- All Stage 3-4
- ECOG PS - PFTs (DLCO, FEV1)- Tissue
Workup
![Page 25: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/25.jpg)
• Pancoast Tumor: Apical Tumor + Chest wall inv
• Pancoast Syndrome: – Apical tumor + shoulder pain/brachial plexus palsy– +/- Horner’s Syndrome
Workup – Pancoast Tumor
![Page 26: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/26.jpg)
• Endocrine – If diffuse complaints (N/V/lethargy) & not yet on tx
• CBC, CMP further w/u pending former
• Neurologic– If weakness that is focal & improves w/steroids
• C/T/L spine MRI
– If multifocal consider• r/o Steroid myopathy – Check CK• Neuro c/s
– Nerve conduction studies, EMG CSF, Neuro/Immune Ab panel
Workup – Paraneoplastic d/o’s
![Page 27: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/27.jpg)
Workup- Paraneoplastic- Endocrine
![Page 28: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/28.jpg)
Workup- Paraneoplastic- Neurologic
![Page 29: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/29.jpg)
Workup- Paraneoplastic- Neurologic
![Page 30: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/30.jpg)
Pathology
![Page 31: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/31.jpg)
Pathology - AdenocarcinomaDiffuse TTF1+Focal p63+CK7+/CK20(-)
Multiple Histologic Subtypes: mixed, acinar, papillary, nonmucinous, mucinous, solid, fetal, signet, clear cell
Each w/varying genetics of unclear significance
NonsmokerEGFR mutations +f
SmokerKRAS mutations +f
BothTP53 mutations >70%Smokers>Nonsmokers
ALK mut 7%
![Page 32: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/32.jpg)
Pathology – Squamous Cell Carcinoma CK5/6+
Keratin +<25% TTF1<25% CK7+
EGFR amp in 30%(-) f of KDR mutKRAS (-)p53 mut + in >60%
![Page 33: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/33.jpg)
Pathology – Large Cell NE Carcinoma
Chromograninor Synaptophysin or NCAM +
50% TTF1+<25% CK1/5/10/14/20
*High propensity for CNSmetastasis
![Page 34: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/34.jpg)
-PathologySmall Cell Carcinoma
EMA+TTF1+
+/- (25%) ChromograninSynaptophysinNCAMNeuron specific Enolase
Amp in c-Metp53 mut in >75%Rare:EGFR,ALK,KRAS
![Page 35: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/35.jpg)
- TNM Staging in 1972 for NSCLC
- Updated by Cliff Mountain in 1987 (4th)- Previously just MD Anderson data used for validation
- Updated by Cliff Mountain in 1997 (5th)
- The 6th Ed project started in 1998
- Two workshops in Brompton Hospital in 1998
- Committee reformed in 2002
- Revised by Sobin in 2002 NY (6th)
- New Staging by IASLC in 2009 (7th)
Lung Cancer Staging History
![Page 36: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/36.jpg)
Changes to T Staging from 6th Ed.
T1 broken into T1a, Tb
T2 broken into T2a, T2bT2 given upper limit of 7cm
T3 now >7cm
Multiple tumor nodules in same lobe changed from T4 T3
Multiple tumor nodules in same lung but different lung from M1 T4
![Page 37: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/37.jpg)
• Nodal staging was once divergent
in classification
• Naruke (Japan) & ATS/LCSG
had separate systems which
were reconciled in the AJCC in 1996
• Conflict: – ATS 10L & 10R vs. Naruke 10 (hilar) &
4 (lower paratracheal, including azygos nodes)
• Resolution: LN drainage
& anatomy is simplified w/zones– All nodes w/in mediastinal pleural reflection
= N2 nodes
– All LN stations distal to mediastinal pleural
reflection & w/in visceral pleura = N1 nodes
Changes to N Staging form 6th Ed.
Regional Lymph Node Classification for Lung Cancer Staging Clifton F. Mountain and Carolyn M. Dresler CHEST June 1997 vol. 111 no. 6 1718-1723
![Page 38: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/38.jpg)
• Historically Stage 3 disease has been heterogenous based on TNM
• Widely regarded to have a uniformly poor prognosis based on OS
Controversies in Staging
![Page 39: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/39.jpg)
• None were made to Nodal staging, however the N2 grouping remains a heterogeneous Stage grouping
• Staging LN by # Chains may be more useful than regions
Changes to Staging
Re-appraisal of N2 disease by lymphatic drainage pattern for non-small-cell lung cancers: By terms of nodal stations, zones, chains, and a composite. Zheng H, Wang LM, Bao F, Jiang GN, Xie HK, Ding JA, Hu XF, Chen C. Lung Cancer. 2011 Apr 27.
![Page 40: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/40.jpg)
Changes to M Staging
Multiple tumor nodules in same lung M1 T4
M1 subdivided into M1a, M1b
Malignant pleural effusion reclassified from T4 M1a
Separate nodules in contralateral lung M1a
M1b = distant metastases
![Page 41: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/41.jpg)
Staging- Role for Molecular Markers- Multiple Markers have been suggested in several Metanalyses
Favorablebcl-2EGFR Mut
AdverseTTF1Cox2EGFR AmpRasKi67HER2VEGFMicrovascular Densityp53Aneuploidy
- Many are being used to stratify treatment, none are being used for staging
![Page 42: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/42.jpg)
7th Edition AJCC Staging – T Stage• Tx: No gross dz, but +cytology
• T1: <3cm• T1a: <2cm in greatest dimension
• T1b: >2cm, <3cm in greatest dimension
• T2: if 3-7cm and involves: main bronchus, 2cm or more distal to carina, invades visceral pleura, associated w/partial atelectasis or obstructive pneumonitis
• T2a: >3cm, <5cm in greatest dimension
• T2b: >5cm, <7cm in greatest dimension
• T3: >7cm or invades: – parietal pleura, CW, diaphragm, phrenic n, mediastinal pleura, parietal pericardium, <2cm
from carina, associated w/obstruction/atelectasis of entire lung
• T4: Any Size byt invades:– mediastinum, heart, great vessels, trachea, recurrent laryngeal n., esophagus, vertebral body,
carina, separate tumor nodule in different ipsilateral lobe
![Page 43: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/43.jpg)
7th Edition AJCC Staging – N&M Stage• N Stage
– Nx: Regional LN cannot be assessed
– N0: No LN mets
– N1: Ipsilateral peribronchial, hilar, intrapulmonary LNs (>Lvl 10)
– N2: Ipsilateral mediastinal (< Lvl 7) &/or subcarinal LNs
– N3: Contralateral mediastinal, hilar, or contralateral scalene/SCV LNs
• M Stage– M0: No distant metastasis
– M1: Distant metastasis• M1a: Separate tumor nodule in contralateral lobe or malignant pleural effusion
• M1b: Distant Metastasis
![Page 44: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/44.jpg)
7th Edition AJCC Staging – SCLC• 25-35% Limited Stage
– Confined to one hemithorax and regional nodes (conventionally one RT field)
• 65-75% Extensive Stage – -10% bave brain metastases at presentation
– Any disease not fitting into the above
![Page 45: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/45.jpg)
Current Consensus Nodal Map
Regional Lymph Node Classification for Lung Cancer Staging Clifton F. Mountain and Carolyn M. Dresler CHEST June 1997 vol. 111 no. 6 1718-1723
![Page 46: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/46.jpg)
Regional Lymph Node Classification for Lung Cancer Staging Clifton F. Mountain and Carolyn M. Dresler CHEST June 1997 vol. 111 no. 6 1718-1723
![Page 47: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/47.jpg)
![Page 48: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/48.jpg)
Stage Grouping
![Page 49: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/49.jpg)
Patterns of Spread•Nodal
–Zones
–Stations
–Chains
•Distant–Brain
–Bone
–Adrenal Nodule
–Contralateral Lung
–Liver
–Pericardium
–Kidneys
–Subcutaneous
![Page 50: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/50.jpg)
RU Mediastinum - R pre/paratracheal LN chain (4R, 2R, Sup 10R) - Tracheo-esophageal chain (LN Lvl 3p) - R. Phrenic n. chain (LN Lvl 3a)LU Mediastinum - Preaorto-carotid chain (LN Lvl 5,6) - L. Superior bronchial recurrent chain (Lvl 10L, 4L, 2L) - L. Phrenic n. Chain (Lvl 3a)Lower Mediastinum - Common inter-tracheobronchial chain (Lvl 7, 8, 10R, 10L) - Inf Pulm l. chain (LN not relevant-not pictured)
M. Riquet, A. Arame, C. Foucault and F. Le Pimpec Barthes, Prognostic classifications of lymph node involvement in lung cancer and current International Association for the Study of Lung Cancer descriptive classification in zones. Interact Cardiovasc Thorac Surg, 11 (2010), pp. 260–264.
Pattern of Spread
![Page 51: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/51.jpg)
Re-appraisal of N2 disease by lymphatic drainage pattern for non-small-cell lung cancers: By terms of nodal stations, zones, chains, and a composite. Zheng H, Wang LM, Bao F, Jiang GN, Xie HK, Ding JA, Hu XF, Chen C. Lung Cancer. 2011 Apr 27.
![Page 52: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/52.jpg)
Patterns of Spread
RUL (black nodes)RML (dark gray nodes)RLL (striped nodes)LUL (crosshatched nodes)LLL (dotted nodes)
Radiographics. 2004 Mar-Apr;24(2):419-34. Patterns of lymphadenopathy in thoracic malignancies. Sharma A, Fidias P, Hayman LA, Loomis SL, Taber KH, Aquino SL.
![Page 53: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/53.jpg)
• No Accepted LN # for sampling• ATS recs sampling reachable nodal stations• AJCC recs
– R. Lung: 2R, 4R, 7, 10R, 11R– L. Lung: 5, 6, 7, 10L, 11L– Lower Lobe: Sample Lvl 9
• Ideal exploration (for staging) would include >= 1 LN node from the R & L, Superior & Inf paratracheal & subcarinal stations.
Mediastinal Staging
![Page 54: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/54.jpg)
• NonInvasive– PET– CT– MRI
• Invasive– Trans Thoracic Needle Aspiration – EUS FNA– EBUS w/TBNA – Cervical Mediastinoscopy– Extended Cervial Mediastinoscopy– Thoracoscopy – Mediastinoscopy + Ant
Mediastinotomy – Radical Video-Assisted
Mediastinoscopic Lymphadenectomy
– Transcervical Extended Mediastinal Lymphadenectomy- TEMLA
Mediastinal Staging
![Page 55: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/55.jpg)
Summary ROC curve for imaging mediastinal lymph nodes that are > 1 cm diameter w/standard CT scanning
Chest. 2003 Jan;123(1 Suppl):137S-146S. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Toloza EM, Harpole L, McCrory DC.
Mediastinal Staging - Noninvasive
![Page 56: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/56.jpg)
Summary ROC curve for imaging mediastinal lymph nodes that are > 1 cm diameter w/FDG PET
Chest. 2003 Jan;123(1 Suppl):137S-146S. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Toloza EM, Harpole L, McCrory DC.
Mediastinal Staging - Noninvasive
![Page 57: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/57.jpg)
Sensitivity ~ 100% & Specificity ~ 84% for USPIO in predicting LAD
J Magn Reson Imaging. 2000 Dec;12(6):899-904. MR imaging of mediastinal lymph nodes: evaluation using a superparamagnetic contrast agent. Pannu HK, Wang KP, Borman TL, Bluemke DA.
Mediastinal Staging - Noninvasive
![Page 58: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/58.jpg)
• Invasive Staging Techniques– Trans Thoracic Needle Aspiration – EUS FNA – EBUS w/TBNA – Cervical Mediastinoscopy– Extended Cervical Mediastinoscopy– Thoracoscopy – Mediastinoscopy + Ant Mediastinotomy – Transcervical Extended Mediastinal Lymphadenectomy- TEMLA
Mediastinal Staging - Invasive
![Page 59: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/59.jpg)
Mediastinal Staging - Invasive
• Invasive Staging Techniques – Summary of Nodal Accessibility
= least invasive way of staging LN station
![Page 60: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/60.jpg)
Surgical Assessment and Intraoperative Management of Mediastinal Lymph Nodes in Non-Small Cell Lung Cancer Review Article. The Annals of Thoracic Surgery, Volume 84, Issue 3, September 2007, Pages 1059-1065
Mediastinal Staging – Invasive - Utility
![Page 61: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/61.jpg)
Mediastinal Staging – Invasive - TBNA
Chest. 2011 Feb;139(2):395-401. 2010 Oct 28. Rapid on-site evaluation of transbronchial aspirates in the diagnosis of hilar and mediastinal adenopathy: a randomized trial. Trisolini R, Cancellieri A, Tinelli C, Paioli D, Scudeller L, Casadei GP, Parri SF, Livi V, Bondi A, Boaron M, Patelli M.
![Page 62: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/62.jpg)
Mediastinal Lymph Node Sampling
Complication rate 10.1%
Possible Complications-Hematoma-Recurrent Laryngeal n. injury-Infection-Pneumothorax
Mediastinal Staging – Invasive - Mediastinoscopy
![Page 63: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/63.jpg)
Mediastinal Staging – Invasive
J Thorac Cardiovasc Surg. 2011 Sep 30. A prospective controlled trial of endobronchial ultrasound-guided transbronchial needle aspiration compared with mediastinoscopy for mediastinal lymph node staging of lung cancer. Yasufuku K, Pierre A, Darling G, de Perrot M, Waddell T, Johnston M, da Cunha Santos G, Geddie W, Boerner S, Le LW, Keshavjee S.
EBUS & mediastinoscopy concordance rate for staging in 136 patients (91%; Kappa, 0.8; 95% confidence interval, 0.7-0.9).
No significant differences were found between EBUS-TBNA & mediastinoscopy in determining the true pathologic N stage (McNemar's test, P = .78).
EBUS Med
Complications 0% 2.6%%
EBUS Med
Sensitivity 81% 79%
Spec 100% 100%
NPV 91% 90%
PPV 100% 100%
Accuracy 93% 93%
153 NSCLC patients
EBUS TBNA
Mediastinoscopy
Prospective Trial EBUS vs. Mediastinoscopy
![Page 64: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/64.jpg)
• Neuro
• Abdominal
• MSK
Staging Distant Disease
![Page 65: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/65.jpg)
• Clinical Neuro Eval
• Clinical Abdominal Eval
• Clinical MSK Eval
Chest. 2003 Jan;123(1 Suppl):137S-146S. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Toloza EM, Harpole L, McCrory DC.
Staging Distant Disease
![Page 66: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/66.jpg)
• Staging
• Target Delineation
• Prognosis
• Follow-up Imaging
• Technique
• Investigational Agents
Role for PET
![Page 67: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/67.jpg)
Role for PET – Staging
Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):78-86. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Bradley J, Thorstad WL, Mutic S, Miller TR, Dehdashti F, Siegel BA, Bosch W, Bertrand RJ.
![Page 68: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/68.jpg)
Role for PET – Target Delineation
Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):78-86. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Bradley J, Thorstad WL, Mutic S, Miller TR, Dehdashti F, Siegel BA, Bosch W, Bertrand RJ.
![Page 69: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/69.jpg)
• Sensitivity and specificity of FDG-PET/CT for detecting recurrence has historically been estimated to range from 93% to 100% and 82% to 92%, respectively
Mac Manus MP, Ding Z, Hogg A, et al. Association between pulmonary uptake of fluorodeoxyglucose detected by positron emission tomography scanning after radiation therapy for nonsmall-cell lung cancer and radiation pneumonitis. Int J Radiat Oncol Biol Phys. [Epub ahead of print July 31, 2010].
Role for PET in follow-up
![Page 70: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/70.jpg)
• Hoopes et al demonstrated that moderate HM activity may persist for up to 2 yrs after completion of SBRT w/out definite evidence of recurrence. – Validated prospectively
Mac Manus MP, Ding Z, Hogg A, et al. Association between pulmonary uptake of fluorodeoxyglucose detected by positron emission tomography scanning after radiation therapy for nonsmall-cell lung cancer and radiation pneumonitis. Int J Radiat Oncol Biol Phys. [Epub ahead of print July 31, 2010].
Role for PET in follow-up for SBRT
![Page 71: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/71.jpg)
• A study from the University of Pittsburgh demonstrated a significant correlation with mean SUV and treatment response. (mean SUV decreases)– Complete responders, 94%, – Partial responders 48%, – Stable disease 28%– Patients with progressive disease had an SUV decrease of only 0.4%.
• However this study only had once LR, so their definition of CR, PR, SD is arbitrary and w/out clinical relevance
Clin Lung Cancer. 2008 Jul;9(4):217-21. Fractionated stereotactic body radiation therapy in the treatment of primary, recurrent, and metastatic lung tumors: the role of positron emission tomography/computed tomography-based treatment planning. Coon D, Gokhale AS, Burton SA, Heron DE, Ozhasoglu C, Christie N.
Role for PET in follow-up
![Page 72: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/72.jpg)
• “Degree of post-treatment FDG uptake in patients receiving conventional radiation therapy for NSCLC has also been demonstrated to be a predictor of radiation pneumonitis”
- Albert Chang, Jeffrey Bradley PRO 2011
Mac Manus MP, Ding Z, Hogg A, et al. Association between pulmonary uptake of fluorodeoxyglucose detected by positron emission tomography scanning after radiation therapy for nonsmall-cell lung cancer and radiation pneumonitis. Int J Radiat Oncol Biol Phys. [Epub ahead of print July 31, 2010].
Role for PET in follow-up
• Used multivariate ordinal regression to look for covariates that would predict for pneumonitis
• No interactions tested for, data didn’t fit test assumptions• Radiation Pneumonitis is still a clinical diagnosis
![Page 73: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/73.jpg)
• Reduces tumor vol (14-34%), & results in + SUVmax
Role for PET in Target Delineation: Technique
Med Phys. 2004 Dec;31(12):3179-86. Four-dimensional (4D) PET/CT imaging of the thorax. Nehmeh SA, Erdi YE, Pan T, Pevsner A, Rosenzweig KE, Yorke E, Mageras GS, Schoder H, Vernon P, Squire O, Mostafavi H, Larson SM, Humm JL.
![Page 74: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/74.jpg)
• IASLC meta-analysis showed that a high lesion SUV is a poor prognosticfactor for OS in patients w/locallyadvanced NSCLC
• If 1o w/ max SUV >15 (-) in OS &were more likely to have mediastinalLN involvement
• Reduction in SUVmax by >80% is 96% accurate for predicting pCR
• Reduction in SUVmax by >20% w/chemo portendsimproved PFS, and OS
Role for PET in Prognosis
J Thorac Oncol. 2010 May;5(5):612-9. Primary tumor SUV measured on FDGPET is of prognostic value for survival in NSCLC: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the IASLC Staging Project. Paesmans M, Berghmans T, Dusart M, Garcia C, Hossein-Foucher C, Lafitte JJ, Mascaux C, Meert AP, Roelandts M, Scherpereel A, Terrones Munoz V, Sculier JP
JCO, Vol 21, Issue 14 (July), 2003: 2651-2657 PET in NSCLC: Prediction of Response to Chemo by Quantitative Assessment of Glucose Use. Weber, Petersen, Schmidt, Tyndale-Hines, Link, Peschel, Schwaiger
![Page 75: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/75.jpg)
• Early Stage- f/u visits– Post Tx: @ 2 mo then q4mo thereafter for 2 yrs
• 2 mo visit to establish baseline CT prior to tx change• q4mo visits: CT w/out contrast if no concerns
– 2 Yrs Post Tx: q6mo for 5 yrs w/CT– 5 yrs Post Tx: q1yr w/CT
• Advanced Stage- f/u visits– Post Tx: @ 2mo then q3 mo for 1 yr alternating w/MedOnc– 1 yr post Tx: q4mo w/CT (MedOnc orders scans)– 2yr post Tx: q6mo for 5yrs w/CT (usually MedOnc & RadOnc
same day)
Lung Cancer Management:
![Page 76: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/76.jpg)
If new dyspnea while on treatment:- r/o Alternative Causes
- i.e. PE- Optimize Inhalers if not already done based on PFTs
If new dyspnea in f/u:-r/o Alternative Causes
- i.e. PE-Optimize Inhalers if not already done based on PFTs-Consider rpt PFTs-Review stability of patient’s COPD, i.e. would they benefit from prevention?
Lung Cancer Management- Dyspnea
![Page 77: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/77.jpg)
![Page 78: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/78.jpg)
The frequency of exacerbations (P=0.01):-Azithro: 1.48 per patient-yr -Placebo: 1.83 per patient-yr
-HR for having an acute COPD exacerbation per patient-yr in the azithromycin group was 0.73 (95% CI, 0.63 to 0.84) (P<0.001).
Lung Cancer Management- Dx & Tx of ExacerbationsProspective Trial-Azithromycin vs. Placebo for 1 yr
Endpoint: - # of exacerbations- QOL
![Page 79: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/79.jpg)
Symptoms:- Nonproductive cough- Dyspnea w/exertion- Fever low grade- Pleuritic Chest pain- Malaise
Dx:- Low O2 Sat- A-a gradient on ABG- Depressed DLCO
Tx:- Prednisone 60mg/day for 2 wks w/taper over 3 wks- Consider antibiotics if prolonged taper & other risk factors for immunosuppression
Lung Cancer Management:- Radiation Pneumonitis
![Page 80: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/80.jpg)
![Page 81: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/81.jpg)
Lung Cancer Management: Resources
• MedOnc: – Petty
– Miller
– Ruiz
• CT Surg– Oaks
– Lata (VA)
• Trial Coordinator– Margaret Crowley
– Kathyrn Joesphs-Finlay
• Pulmonary Med: – Conforti– Bellinger
• TOPs Scheduling– Dee Cottrell
• CT Guided Lung Bx– MD - Clark
– Aaron Weldon/Helen Phelps
• VA Scheduling– Emy White
• Lodging etc.– Sally Benfield
![Page 82: Lung cancer overview-JTL](https://reader030.vdocuments.net/reader030/viewer/2022020206/54545851af7959564f8b540a/html5/thumbnails/82.jpg)
European Journal of Cardio-Thoracic Surgery Vol 32, Issue 1, July 2007, Pages 1-8. ESTS guidelines for preoperative lymph node staging for non-small cell lung
cancer. Paul De Leyna, Didier Lardinoisb, Paul E. Van Schilc, Ramon Rami-Portad, Bernward Passlicke, Marcin Zielinskif, David A. Wallerg, Tony Leruta, Walter Wederb